Comparison of secondary prevention measures after myocardial infarction in subjects with and without diabetes mellitus

被引:9
作者
Chowdhury, TA [1 ]
Lasker, SS [1 ]
Hyer, PH [1 ]
机构
[1] Birmingham Heartlands Hosp, Ctr Diabet, Dept Med, Birmingham B9 5SS, W Midlands, England
关键词
diabetes mellitus; myocardial infarction; secondary prevention;
D O I
10.1046/j.1365-2796.1999.00473.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To survey and compare secondary prevention measures in diabetic and non-diabetic patients following myocardial infarction (MI), Design. Follow-up of a cohort of patients who suffered their first: MI 1 year previously. Setting. Three district general hospitals. Main outcome measures. Review 1 year post-MI for signs of left ventricular failure (LVF), serum cholesterol, smelting status, weight, blood pressure and glycaemic control. Assessment of appropriate treatment with aspirin, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors and lipid-lowering therapy before discharge and at least 1 year post-MI. Results, A total of 189 non-diabetic and 86 diabetic patients were studied. Most patients received beta-blockers and aspirin appropriately, and most gave up smoking. In non-diabetic subjects, cholesterol fell significantly (P < 0.05), as did the proportion of patients with cholesterol > 5.5 mmol L-1 (P < 0.05), whereas cholesterol did not fall significantly in diabetic subjects, due to a lower proportion of patients being on lipid-lowering therapy (27.5 vs. 37.9%). A higher proportion of non-diabetic patients with LVF were treated with ACE inhibitors compared with diabetic subjects (73.6 vs. 61.0%), Glycaemic control did not improve in the diabetic subjects. Conclusions. Patients with diabetes do not receive optimal secondary prevention measures compared with their non-diabetic counterparts. This issue needs to be addressed by all units dealing with patients with diabetes in order to reduce the mortality and morbidity of MI in such patients.
引用
收藏
页码:565 / 570
页数:6
相关论文
共 15 条
  • [1] [Anonymous], 1997, Eur Heart J, V18, P1569
  • [2] [Anonymous], 1988, LANCET, V2, P349
  • [3] BALL SG, 1993, LANCET, V342, P821
  • [4] ACEBUTOLOL, ATENOLOL, AND PROPRANOLOL AND METABOLIC RESPONSES TO ACUTE HYPOGLYCEMIA IN DIABETICS
    DEACON, SP
    KARUNANAYAKE, A
    BARNETT, D
    [J]. BRITISH MEDICAL JOURNAL, 1977, 2 (6097) : 1255 - 1257
  • [5] Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
    Haffner, SM
    Lehto, S
    Rönnemaa, T
    Pyörälä, K
    Laakso, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (04) : 229 - 234
  • [6] Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus
    Malmberg, K
    [J]. BRITISH MEDICAL JOURNAL, 1997, 314 (7093) : 1512 - 1515
  • [7] Fortnightly review - Secondary prevention in acute myocardial infarction
    Mehta, RH
    Eagle, KA
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1998, 316 (7134): : 838 - 842
  • [8] A PROSPECTIVE-STUDY OF MORTALITY AMONG MIDDLE-AGED DIABETIC-PATIENTS (THE LONDON COHORT OF THE WHO MULTINATIONAL STUDY OF VASCULAR-DISEASE IN DIABETICS) .1. CAUSES AND DEATH RATES
    MORRISH, NJ
    STEVENS, LK
    HEAD, J
    FULLER, JH
    JARRETT, RJ
    KEEN, H
    [J]. DIABETOLOGIA, 1990, 33 (09) : 538 - 541
  • [9] PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801
  • [10] EFFECT OF CAPTOPRIL ON MORTALITY AND MORBIDITY IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL-INFARCTION - RESULTS OF THE SURVIVAL AND VENTRICULAR ENLARGEMENT TRIAL
    PFEFFER, MA
    BRAUNWALD, E
    MOYE, LA
    BASTA, L
    BROWN, EJ
    CUDDY, TE
    DAVIS, BR
    GELTMAN, EM
    GOLDMAN, S
    FLAKER, GC
    KLEIN, M
    LAMAS, GA
    PACKER, M
    ROULEAU, J
    ROULEAU, JL
    RUTHERFORD, J
    WERTHEIMER, JH
    HAWKINS, CM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (10) : 669 - 677